Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. The anonymized data is commercialized as clinical evidence.
|07 Dec 2021||$0.38||$0.01||2.74%||791,161||$0.38||$0.40||$0.38|
|06 Dec 2021||$0.37||$-0.03||-7.59%||1,264,230||$0.40||$0.42||$0.35|
|03 Dec 2021||$0.40||$-0.06||-13.33%||1,076,505||$0.45||$0.46||$0.40|
|02 Dec 2021||$0.45||$-0.05||-10.10%||1,265,215||$0.49||$0.49||$0.43|
|01 Dec 2021||$0.50||$0.04||8.70%||1,140,948||$0.46||$0.50||$0.46|
|30 Nov 2021||$0.46||$-0.02||-4.17%||678,065||$0.48||$0.49||$0.46|
|29 Nov 2021||$0.48||$0.04||9.09%||2,397,354||$0.46||$0.50||$0.46|
|26 Nov 2021||$0.44||$-0.06||-12.12%||2,306,546||$0.50||$0.51||$0.44|
|25 Nov 2021||$0.50||$0.06||13.79%||1,482,622||$0.44||$0.50||$0.44|
|24 Nov 2021||$0.44||$0.01||2.35%||2,322,401||$0.44||$0.47||$0.43|
|23 Nov 2021||$0.43||$0.04||10.26%||2,831,135||$0.41||$0.43||$0.38|
|22 Nov 2021||$0.39||$0.07||21.54%||5,612,745||$0.37||$0.40||$0.33|
|18 Nov 2021||$0.33||$0.02||6.56%||858,803||$0.31||$0.34||$0.31|
|17 Nov 2021||$0.31||$-0.05||-14.29%||2,484,847||$0.36||$0.38||$0.31|
|16 Nov 2021||$0.35||$0.01||2.94%||820,603||$0.34||$0.36||$0.34|
|15 Nov 2021||$0.34||$0.01||3.03%||290,332||$0.34||$0.34||$0.33|
|12 Nov 2021||$0.33||$0.01||3.13%||215,707||$0.32||$0.33||$0.32|
|11 Nov 2021||$0.32||$-0.01||-3.08%||248,219||$0.33||$0.33||$0.32|
|10 Nov 2021||$0.33||$0.01||3.17%||78,236||$0.32||$0.33||$0.32|
|09 Nov 2021||$0.32||$-0.03||-8.82%||600,441||$0.34||$0.34||$0.32|
|Mr Matthew (Matt) Callahan||Non-Executive Director||Mar 2018||
Mr Callahan is a life sciences executive with experience. He has been the founder, CEO or Executive Director of a number of pharmaceutical and health tech companies which includes Churchill Pharma Inc. He has led the development of four pharmaceutical products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in lifesciences, technology and other sectors.
|Dr Stewart James Washer||Executive ChairmanExecutive Director||Mar 2018||
Dr Washer has 25 years of CEO and Board experience in medical and agrifood biotech companies. Stewart has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd.
|Sir John Tooke||Non-Executive Director||Feb 2020||
Sir Tooke is Executive Chairman of Academic Health Solutions, a start-up Group offering advice to clients internationally on medical research and health service transformation. He is Senior Independent Director at BUPA Chile and was until 2019 non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council. He is the Chair of Collaboration for the Advancement of Medical Innovation (CASMI) UCL and Chaired the Oversight Group for the Academy of Medical Sciences project. He also served as an Review Board Member for Google Health (UK). Sir Tooke was Head of the School of Life and Medical Sciences at University College London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 - 2015. He is the Past President of the Academy of Medical Sciences in the UK. Sir Tooke has 30 years experience as a consultant physician specialising in diabetes, endocrinology, vascular medicine and internal medicine with research experience (basic biomedical, medicine, and health research and also includes improvement science) recognised through Fellowship of the Academy of Medical Sciences. He held a Board position at the Francis Crick Institute (2011 - 2015) and was a Member of the Council for Science & Technology (2011-2015) reporting to the Prime Minister (UK).
|Dr Michael Winlo||Managing Director||Nov 2019||
Dr Winlo was CEO at Linear Clinical Research Ltd (Linear) until October 2019, a company that provides clinical trial services for US and Asia-based biotech companies. Linear adopt electronic data capture technology. Dr Winlo retains a Directorship at Linear. Prior to Linear, He was Health Lead at Palantir Technologies, a Big Data company based in Silicon Valley California.
|Dr Alistair Vickery||Executive Director||Nov 2018||
Dr Vickery has expertise in clinical practice, health service management, clinical and educational research and board director skills. He is adjunct Clinical Professor of Primary Health Care at the University of Western Australia and Notre Dame University. He is the clinical lead of the research group CHASM (The Collaborative for Health Care Analysis and Statistical Modelling) which provides analysis modelling to inform clinical service planning and service evaluation. He is Board Chair of Black Swan Health, one of NFP health care service providers in Western Australia.
|Dr Karen Smith||Non-Executive Director||Nov 2021||
Dr Smith has overseen more than 100 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including neuroscience, rare disease, oncology, cardiology, dermatology, oncology and anti-infectives. In addition to R&D and pipeline development, her experience includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma. Dr Smith was recently Chief Medical Officer of Emergent BioSolutions. Dr Smith is also a Director at Antares Pharmaceuticals - developing novel drug delivery technologies and Sangamo Therapeutics and Acceleron Pharmaceuticals - both developing novel treatments for rare diseases, and TeeFib - developing novel treatments for Fibrosis. Previously, Dr Smith served as Executive Vice President, Global Head R&D and Chief Medical Officer of Jazz Pharmaceuticals, Inc. She was also the founding CEO of the Minderoo Foundation's Eliminate Cancer Initiative supported by Andrew Forrest and remains an advisor to that program. She has also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb.
|Mr Simon Lee Robertson||Company Secretary||
|Su-Mei Sain||Chief Financial Officer||
|Simon Lee Robertson||Company Secretary||
|Patrizia Washer||Research Manager||
|Dr Stewart James Washer & Dr Patrizia Derna Washer||28,400,000||11.18%|
|Mal Washer Nominees Pty Ltd||19,600,000||7.71%|
|Mercator Shipwrights Pty Ltd||19,600,000||7.71%|
|Mr Craig Lawrence Darby||19,600,000||7.71%|
|Mr Sufian Ahmad||10,276,210||4.04%|
|Miss Sihong Zeng||6,523,385||2.57%|
|Ms Chunyan Niu||5,882,546||2.32%|
|Lakewest Pty Ltd||5,731,960||2.26%|
|Mr Stephen Peter Somerville||4,900,000||1.93%|
|Rimoyne Pty Ltd||3,831,244||1.51%|
|Woodlands Opportunity Fund Pty Ltd||3,551,757||1.40%|
|Mr Bilal Ahmad||3,450,000||1.36%|
|Mr Pak Lim Kong||3,416,667||1.34%|
|Kobala Investments Pty Ltd||2,600,000||1.02%|
|Mr Lim Pak Kong||2,370,930||0.93%|
|Mr Craig Lawrence Darby i||2,000,000||0.79%|
|Adam James(Araucaria A/C)||1,960,000||0.77%|
|D Schecter Medicine Professional Corporation||1,960,000||0.77%|
|Cs Fourth Nominees Pty Limited||1,683,576||0.66%|
|Canopy Growth Corporation||1,562,500||0.61%|
|Diab Investments Pty Ltd||1,554,622||0.61%|
|Mr Boyun Liu||1,549,962||0.61%|
|Dr Stewart James Washer & Dr Patrizia Derna Washer i||1,325,599||0.52%|